Tuesday, 9 July 2013

Hugh Cleland - Acasti “May In Fact Be In Possession Of A Blockbuster” & Conference Call Details

Acasti Pharma
Shares Outstanding: 79.4 million
Fully Diluted: 91.4 million
Neptune Technologies and Biorresources
Basic Shares: 60.0 million
Fully Diluted: 67.5 million

This morning, U.S. based Life Science Report published an interview with Hugh Cleland, Portfolio Manager for BluMont Capital, titled “Small-Cap Biotechs With Blockbuster Potential: Hugh Cleland.” The interview allowed Mr. Cleland to talk a bit about his funds focus, as well as his interest in Neptune Technologies and Acasti Pharma.

Key points for readers are in his description of Acasti Pharma and its potential.

“The company announced a few weeks ago that it finished enrolling the trial, and we expect to see results this summer. I expect the stock will have a nice run-up into those results. My expectation is that the results will demonstrate that Acasti has, at the very least, a best-in-class ‘fish oil drug’ and may, in fact, be in possession of a blockbuster. I'm awaiting those results with some excitement and optimism. The market caps of both Neptune and Acasti are currently a fraction of where they will be if the trial results are good, and it's been encouraging to see Acasti recently set new all-time highs on the TSX.V in Canada.” (Acasti also trades on NASDAQ under the symbol ACST.)

“There are actually two Phase 2 trials underway right now, and the placebo-controlled double-blind Phase 2 trial [NCT01455844] results are expected in Q1/14. But the open-label results are coming up shortly, likely in July.”
“It's Dr. Harlan Waksal's (Executive VP of Business & Scientific Affairs for Acasti) opinion that the open-label results will be significant enough to move the needle, and will be sufficient to initiate discussions with big pharma on either partnering or a sale.”

To view the interview in its entirety, please click here
Also in a news release issued this morning by Neptune Technologies, the company said it will be holding a conference call on Tuesday, July 16, at 9:00 am ET to present its results for the first quarter of Fiscal 2014 ended May 31st. The Company will also be providing an update on the status of its previously disclosed action plan to resume operations and supply customers. 

The conference call hosts will be Henri Harland, President & CEO, and André Godin, CFO. 

To access the conference call within Canada & the U.S., dial toll-free 1‐877-380-5664. Outside Canada and the U.S., dial 1-631-813-4882. Conference call details: 

Conference Topic: Neptune Technologies & Bioressources first quarter ended May 31, 2013 Results Call
Conference ID:  16440484
Time:     9:00 AM Eastern Time 

Management will accept questions related to the financial results and its operations by telephone during the Q&A period at the end of the presentation.
Questions can also be forwarded in advance or during the presentation to f.harland@neptunebiotech.com.